| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 50 | 2022 | 2028 | 5.250 |
Why?
|
| Diabetes Mellitus | 22 | 2022 | 962 | 3.630 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 30 | 2014 | 149 | 3.540 |
Why?
|
| Muscle, Smooth, Vascular | 14 | 2016 | 457 | 3.180 |
Why?
|
| Cardiovascular Diseases | 23 | 2022 | 1714 | 3.170 |
Why?
|
| Mitochondria, Muscle | 8 | 2021 | 102 | 2.790 |
Why?
|
| Endocrinology | 12 | 2022 | 91 | 2.450 |
Why?
|
| Hypoglycemic Agents | 22 | 2022 | 1026 | 2.270 |
Why?
|
| Mitochondria | 11 | 2022 | 824 | 2.050 |
Why?
|
| Blood Vessels | 5 | 2018 | 192 | 1.960 |
Why?
|
| Endothelium, Vascular | 12 | 2022 | 928 | 1.910 |
Why?
|
| Insulin Resistance | 27 | 2022 | 1163 | 1.850 |
Why?
|
| Diabetic Angiopathies | 10 | 2017 | 274 | 1.740 |
Why?
|
| Aorta | 9 | 2018 | 425 | 1.700 |
Why?
|
| Microcirculation | 7 | 2018 | 155 | 1.660 |
Why?
|
| Metformin | 6 | 2022 | 291 | 1.650 |
Why?
|
| Exercise | 22 | 2022 | 1807 | 1.600 |
Why?
|
| Microvessels | 4 | 2018 | 78 | 1.530 |
Why?
|
| Thiazolidinediones | 11 | 2021 | 156 | 1.460 |
Why?
|
| Adaptation, Physiological | 6 | 2021 | 524 | 1.450 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2016 | 243 | 1.450 |
Why?
|
| Exercise Tolerance | 8 | 2018 | 251 | 1.350 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2022 | 3253 | 1.340 |
Why?
|
| Insulin | 25 | 2022 | 2135 | 1.320 |
Why?
|
| Glucose | 13 | 2022 | 925 | 1.310 |
Why?
|
| Muscle, Skeletal | 16 | 2022 | 1539 | 1.280 |
Why?
|
| Models, Cardiovascular | 3 | 2017 | 180 | 1.270 |
Why?
|
| Catechin | 3 | 2022 | 30 | 1.220 |
Why?
|
| Metabolic Syndrome | 9 | 2019 | 394 | 1.210 |
Why?
|
| Hyperglycemia | 4 | 2017 | 330 | 1.190 |
Why?
|
| Blood Glucose | 22 | 2022 | 1904 | 1.130 |
Why?
|
| Oxygen Consumption | 18 | 2021 | 650 | 1.110 |
Why?
|
| Oxidative Stress | 11 | 2022 | 1254 | 1.080 |
Why?
|
| Rats | 35 | 2022 | 6014 | 1.070 |
Why?
|
| Glucagon-Like Peptide 1 | 6 | 2020 | 104 | 1.070 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2020 | 196 | 1.070 |
Why?
|
| Oxygen | 3 | 2018 | 865 | 1.040 |
Why?
|
| Obesity | 17 | 2022 | 2709 | 0.990 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2021 | 69 | 0.980 |
Why?
|
| Oxidative Phosphorylation | 5 | 2021 | 160 | 0.970 |
Why?
|
| Hypertension | 5 | 2022 | 1200 | 0.950 |
Why?
|
| Insulins | 1 | 2022 | 28 | 0.900 |
Why?
|
| Vascular Diseases | 2 | 2022 | 238 | 0.890 |
Why?
|
| Cardiorespiratory Fitness | 3 | 2019 | 45 | 0.890 |
Why?
|
| Sex Factors | 7 | 2022 | 1921 | 0.870 |
Why?
|
| Humans | 122 | 2022 | 117481 | 0.850 |
Why?
|
| Animals | 65 | 2022 | 34332 | 0.770 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2016 | 206 | 0.760 |
Why?
|
| Blood Flow Velocity | 6 | 2018 | 377 | 0.750 |
Why?
|
| Physical Conditioning, Animal | 3 | 2018 | 231 | 0.750 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2020 | 91 | 0.750 |
Why?
|
| Fatty Acids, Nonesterified | 6 | 2016 | 185 | 0.720 |
Why?
|
| Rats, Wistar | 5 | 2022 | 393 | 0.720 |
Why?
|
| Pterins | 1 | 2018 | 6 | 0.720 |
Why?
|
| Motor Activity | 3 | 2015 | 723 | 0.710 |
Why?
|
| Adipocytes | 7 | 2001 | 195 | 0.680 |
Why?
|
| Leadership | 1 | 2021 | 320 | 0.660 |
Why?
|
| Women's Health | 3 | 2020 | 266 | 0.650 |
Why?
|
| Reference Standards | 12 | 2022 | 195 | 0.640 |
Why?
|
| Vasodilation | 7 | 2022 | 468 | 0.640 |
Why?
|
| Atherosclerosis | 3 | 2011 | 314 | 0.640 |
Why?
|
| Arterioles | 2 | 2016 | 48 | 0.630 |
Why?
|
| Standard of Care | 12 | 2022 | 88 | 0.630 |
Why?
|
| Carotid Arteries | 1 | 2018 | 186 | 0.620 |
Why?
|
| Cell Division | 7 | 2009 | 788 | 0.610 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2021 | 46 | 0.610 |
Why?
|
| Hemorheology | 1 | 2016 | 17 | 0.600 |
Why?
|
| Metabolomics | 2 | 2020 | 537 | 0.600 |
Why?
|
| Glycocalyx | 1 | 2016 | 20 | 0.600 |
Why?
|
| Sex Characteristics | 8 | 2022 | 681 | 0.590 |
Why?
|
| Male | 59 | 2022 | 60409 | 0.580 |
Why?
|
| Capillaries | 1 | 2016 | 104 | 0.580 |
Why?
|
| Nitric Oxide | 3 | 2022 | 869 | 0.580 |
Why?
|
| Diabetes Complications | 2 | 2020 | 226 | 0.570 |
Why?
|
| Needs Assessment | 1 | 2018 | 343 | 0.570 |
Why?
|
| Software | 2 | 2018 | 531 | 0.560 |
Why?
|
| Cardiovascular System | 2 | 2019 | 118 | 0.560 |
Why?
|
| Adamantane | 1 | 2015 | 20 | 0.550 |
Why?
|
| Models, Biological | 4 | 2020 | 1764 | 0.550 |
Why?
|
| Cell Respiration | 3 | 2020 | 81 | 0.540 |
Why?
|
| Dipeptides | 1 | 2015 | 51 | 0.540 |
Why?
|
| Vascular Stiffness | 4 | 2022 | 410 | 0.540 |
Why?
|
| Risk Factors | 16 | 2022 | 9124 | 0.530 |
Why?
|
| Societies, Medical | 13 | 2022 | 754 | 0.520 |
Why?
|
| Regional Blood Flow | 7 | 2020 | 439 | 0.510 |
Why?
|
| Female | 58 | 2022 | 63228 | 0.500 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 38 | 0.490 |
Why?
|
| Adipose Tissue | 6 | 2021 | 665 | 0.480 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 31 | 0.480 |
Why?
|
| Biomedical Research | 2 | 2018 | 598 | 0.470 |
Why?
|
| Disease Models, Animal | 8 | 2018 | 3800 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2005 | 234 | 0.440 |
Why?
|
| Tetrazoles | 1 | 2011 | 29 | 0.430 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2011 | 14 | 0.430 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 505 | 0.430 |
Why?
|
| Hyperinsulinism | 5 | 2019 | 109 | 0.420 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 733 | 0.410 |
Why?
|
| Endothelial Cells | 1 | 2016 | 659 | 0.410 |
Why?
|
| Phosphorylation | 16 | 2013 | 1678 | 0.400 |
Why?
|
| Signal Transduction | 8 | 2022 | 4824 | 0.390 |
Why?
|
| Hypoglycemia | 1 | 2014 | 387 | 0.390 |
Why?
|
| Cell Nucleus | 6 | 2016 | 588 | 0.380 |
Why?
|
| Exercise Therapy | 3 | 2022 | 373 | 0.380 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2009 | 682 | 0.380 |
Why?
|
| Hyperlipidemias | 3 | 2017 | 144 | 0.380 |
Why?
|
| Promoter Regions, Genetic | 5 | 2003 | 1219 | 0.370 |
Why?
|
| Mentoring | 2 | 2022 | 89 | 0.370 |
Why?
|
| Cell Movement | 4 | 2011 | 924 | 0.370 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2021 | 44 | 0.370 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 149 | 0.370 |
Why?
|
| Adolescent | 26 | 2022 | 18875 | 0.370 |
Why?
|
| Aging | 2 | 2018 | 1690 | 0.360 |
Why?
|
| Sirtuin 3 | 2 | 2020 | 50 | 0.360 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2000 | 285 | 0.360 |
Why?
|
| Trans-Activators | 2 | 2001 | 400 | 0.350 |
Why?
|
| Pulmonary Artery | 6 | 2013 | 1073 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2013 | 2855 | 0.340 |
Why?
|
| Cells, Cultured | 14 | 2011 | 4191 | 0.330 |
Why?
|
| Superoxides | 2 | 2020 | 231 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2020 | 398 | 0.320 |
Why?
|
| Leg | 2 | 2021 | 257 | 0.320 |
Why?
|
| Hemodynamics | 3 | 2021 | 1086 | 0.320 |
Why?
|
| Citrate (si)-Synthase | 3 | 2021 | 54 | 0.310 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 1011 | 0.310 |
Why?
|
| Vasoconstriction | 2 | 2018 | 221 | 0.310 |
Why?
|
| Receptor, Insulin | 3 | 1996 | 109 | 0.310 |
Why?
|
| Nuclear Proteins | 2 | 2001 | 623 | 0.300 |
Why?
|
| Echocardiography | 4 | 2020 | 617 | 0.300 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 98 | 0.300 |
Why?
|
| Sulfonylurea Compounds | 3 | 2021 | 46 | 0.300 |
Why?
|
| Adult | 26 | 2022 | 32104 | 0.300 |
Why?
|
| Cell Differentiation | 4 | 2004 | 1790 | 0.300 |
Why?
|
| Incretins | 2 | 2017 | 17 | 0.290 |
Why?
|
| Glycation End Products, Advanced | 1 | 2006 | 70 | 0.290 |
Why?
|
| Peptide Fragments | 3 | 2021 | 718 | 0.280 |
Why?
|
| Pediatric Obesity | 3 | 2017 | 435 | 0.280 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 557 | 0.280 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 349 | 0.280 |
Why?
|
| Overweight | 2 | 2022 | 494 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2009 | 321 | 0.280 |
Why?
|
| Down-Regulation | 2 | 2010 | 646 | 0.270 |
Why?
|
| Monosaccharide Transport Proteins | 4 | 2001 | 46 | 0.270 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 585 | 0.270 |
Why?
|
| Kinetics | 9 | 2017 | 1685 | 0.270 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 503 | 0.270 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 38 | 0.270 |
Why?
|
| Time Management | 1 | 2004 | 18 | 0.260 |
Why?
|
| Diabetic Nephropathies | 2 | 2020 | 290 | 0.260 |
Why?
|
| Lipids | 4 | 2022 | 636 | 0.260 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 14 | 0.250 |
Why?
|
| Double-Blind Method | 6 | 2019 | 1690 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 92 | 0.240 |
Why?
|
| Middle Aged | 19 | 2020 | 28654 | 0.240 |
Why?
|
| Coronary Disease | 2 | 2003 | 408 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 441 | 0.230 |
Why?
|
| Comorbidity | 4 | 2022 | 1649 | 0.230 |
Why?
|
| Brachial Artery | 3 | 2019 | 197 | 0.230 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2002 | 43 | 0.230 |
Why?
|
| Diastole | 2 | 2020 | 164 | 0.230 |
Why?
|
| Sitagliptin Phosphate | 2 | 2019 | 28 | 0.230 |
Why?
|
| Physical Fitness | 3 | 2013 | 188 | 0.220 |
Why?
|
| Ecdysterone | 1 | 2001 | 3 | 0.220 |
Why?
|
| Overnutrition | 1 | 2022 | 45 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2001 | 233 | 0.220 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 228 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 1 | 2022 | 234 | 0.220 |
Why?
|
| Transcription Factors | 6 | 2012 | 1623 | 0.210 |
Why?
|
| Young Adult | 13 | 2021 | 11069 | 0.210 |
Why?
|
| Cattle | 4 | 2009 | 950 | 0.210 |
Why?
|
| Retinal Diseases | 1 | 2022 | 68 | 0.210 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2021 | 71 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 414 | 0.210 |
Why?
|
| Faculty, Medical | 1 | 2004 | 256 | 0.210 |
Why?
|
| Exercise Test | 7 | 2016 | 617 | 0.210 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 177 | 0.210 |
Why?
|
| Glucose Intolerance | 1 | 2022 | 137 | 0.200 |
Why?
|
| Glutathione | 1 | 2022 | 330 | 0.200 |
Why?
|
| Antimycin A | 1 | 2020 | 11 | 0.200 |
Why?
|
| Muscle Contraction | 3 | 2017 | 420 | 0.200 |
Why?
|
| Triglycerides | 4 | 2013 | 551 | 0.200 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 145 | 0.200 |
Why?
|
| Glycopeptides | 1 | 2021 | 63 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 104 | 0.200 |
Why?
|
| Autophagy | 2 | 2016 | 327 | 0.200 |
Why?
|
| Age Factors | 3 | 2021 | 3221 | 0.200 |
Why?
|
| Protein Kinases | 2 | 2020 | 325 | 0.200 |
Why?
|
| Electron Transport Complex I | 1 | 2020 | 38 | 0.200 |
Why?
|
| Aged | 15 | 2022 | 20243 | 0.190 |
Why?
|
| Thiazoles | 2 | 2002 | 119 | 0.190 |
Why?
|
| Thrombosis | 2 | 2002 | 286 | 0.190 |
Why?
|
| Congresses as Topic | 2 | 2020 | 205 | 0.190 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 20 | 0.190 |
Why?
|
| Perfusion | 2 | 2018 | 167 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 998 | 0.190 |
Why?
|
| Thinness | 3 | 2021 | 94 | 0.190 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 94 | 0.190 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 1999 | 14 | 0.190 |
Why?
|
| Glucose Tolerance Test | 2 | 2018 | 366 | 0.190 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2010 | 293 | 0.190 |
Why?
|
| Body Mass Index | 6 | 2018 | 2076 | 0.190 |
Why?
|
| Mice | 18 | 2022 | 15530 | 0.190 |
Why?
|
| Fibroblasts | 4 | 2016 | 850 | 0.190 |
Why?
|
| Inservice Training | 1 | 2020 | 111 | 0.190 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 421 | 0.180 |
Why?
|
| Oxidation-Reduction | 3 | 2020 | 957 | 0.180 |
Why?
|
| Pulse Wave Analysis | 4 | 2022 | 193 | 0.180 |
Why?
|
| Transfection | 6 | 2007 | 910 | 0.180 |
Why?
|
| Life Style | 1 | 2021 | 408 | 0.180 |
Why?
|
| Apoptosis | 3 | 2007 | 2572 | 0.180 |
Why?
|
| Cell Line | 8 | 2016 | 2832 | 0.180 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 2 | 2021 | 9 | 0.180 |
Why?
|
| PPAR gamma | 3 | 2022 | 192 | 0.180 |
Why?
|
| Microscopy, Video | 1 | 2018 | 23 | 0.180 |
Why?
|
| Deoxyglucose | 3 | 1993 | 53 | 0.180 |
Why?
|
| Homocysteine | 1 | 2019 | 135 | 0.180 |
Why?
|
| Carbohydrates | 1 | 2018 | 59 | 0.170 |
Why?
|
| Echocardiography, Doppler | 3 | 2016 | 119 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2017 | 282 | 0.170 |
Why?
|
| Mentors | 1 | 2020 | 156 | 0.170 |
Why?
|
| Venoms | 2 | 2016 | 32 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2022 | 367 | 0.170 |
Why?
|
| Automation | 1 | 2018 | 78 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2022 | 9333 | 0.170 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2010 | 87 | 0.170 |
Why?
|
| Bicycling | 2 | 2017 | 79 | 0.170 |
Why?
|
| Pregnancy | 6 | 2022 | 5540 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1524 | 0.170 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 139 | 0.170 |
Why?
|
| Mitochondria, Heart | 1 | 2018 | 96 | 0.170 |
Why?
|
| Cysteine | 1 | 2019 | 200 | 0.170 |
Why?
|
| Weight Gain | 1 | 2021 | 513 | 0.170 |
Why?
|
| Glucose Clamp Technique | 4 | 2016 | 203 | 0.170 |
Why?
|
| Convection | 1 | 2017 | 7 | 0.170 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 276 | 0.170 |
Why?
|
| Serine | 5 | 2021 | 134 | 0.170 |
Why?
|
| Capillary Resistance | 1 | 2017 | 5 | 0.160 |
Why?
|
| Biomarkers | 5 | 2021 | 3574 | 0.160 |
Why?
|
| Oxyhemoglobins | 1 | 2017 | 19 | 0.160 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 111 | 0.160 |
Why?
|
| Superoxide Dismutase | 3 | 2021 | 362 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 1995 | 1382 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 234 | 0.160 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 38 | 0.160 |
Why?
|
| Inflammasomes | 1 | 2018 | 122 | 0.160 |
Why?
|
| Diffusion | 1 | 2017 | 125 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1188 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 170 | 0.160 |
Why?
|
| Albuminuria | 2 | 2020 | 185 | 0.160 |
Why?
|
| United States | 9 | 2022 | 12756 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 33 | 0.160 |
Why?
|
| Ventricular Fibrillation | 1 | 2017 | 66 | 0.160 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 430 | 0.150 |
Why?
|
| Disease | 1 | 2017 | 81 | 0.150 |
Why?
|
| Hypoxia | 4 | 2013 | 923 | 0.150 |
Why?
|
| Heart Failure | 1 | 2010 | 2023 | 0.150 |
Why?
|
| Blood Pressure | 6 | 2021 | 1687 | 0.150 |
Why?
|
| Blood Viscosity | 1 | 2016 | 23 | 0.150 |
Why?
|
| Leptin | 2 | 2017 | 236 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 411 | 0.150 |
Why?
|
| Adiponectin | 2 | 2016 | 213 | 0.150 |
Why?
|
| Swine, Miniature | 2 | 2013 | 70 | 0.150 |
Why?
|
| Luteinizing Hormone | 1 | 2017 | 187 | 0.150 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 65 | 0.150 |
Why?
|
| Immediate-Early Proteins | 1 | 2016 | 61 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 4 | 2013 | 297 | 0.150 |
Why?
|
| Child | 11 | 2022 | 18613 | 0.150 |
Why?
|
| Forearm | 2 | 2015 | 109 | 0.150 |
Why?
|
| Menopause | 1 | 2019 | 265 | 0.150 |
Why?
|
| Chromans | 1 | 1995 | 21 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2022 | 499 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2017 | 157 | 0.150 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2017 | 220 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 524 | 0.140 |
Why?
|
| Capillary Permeability | 1 | 2016 | 146 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2016 | 672 | 0.140 |
Why?
|
| PC12 Cells | 3 | 2000 | 40 | 0.140 |
Why?
|
| Kidney | 4 | 2021 | 1236 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2016 | 81 | 0.140 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2016 | 71 | 0.140 |
Why?
|
| Vascular Resistance | 1 | 2017 | 380 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 584 | 0.140 |
Why?
|
| Goals | 1 | 2017 | 148 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2022 | 6420 | 0.140 |
Why?
|
| Islets of Langerhans | 4 | 2007 | 715 | 0.140 |
Why?
|
| Quality of Life | 2 | 2021 | 2351 | 0.140 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 315 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 862 | 0.140 |
Why?
|
| Biological Assay | 1 | 2016 | 115 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 291 | 0.140 |
Why?
|
| Organelle Biogenesis | 1 | 2015 | 14 | 0.140 |
Why?
|
| Genes, Reporter | 4 | 2016 | 282 | 0.140 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 65 | 0.140 |
Why?
|
| Hyperandrogenism | 1 | 2015 | 14 | 0.140 |
Why?
|
| Phosphates | 2 | 1993 | 176 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 780 | 0.140 |
Why?
|
| Adiposity | 2 | 2017 | 504 | 0.140 |
Why?
|
| Swine | 4 | 2017 | 734 | 0.140 |
Why?
|
| Ventricular Function | 1 | 2015 | 64 | 0.130 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1994 | 53 | 0.130 |
Why?
|
| Myocardium | 1 | 2020 | 1000 | 0.130 |
Why?
|
| Neurons | 1 | 2003 | 1419 | 0.130 |
Why?
|
| Endothelium | 1 | 2015 | 122 | 0.130 |
Why?
|
| CREB-Binding Protein | 3 | 2006 | 28 | 0.130 |
Why?
|
| Cholesterol, LDL | 3 | 2014 | 310 | 0.130 |
Why?
|
| American Heart Association | 1 | 2015 | 306 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 216 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2018 | 2805 | 0.130 |
Why?
|
| Cell Survival | 4 | 2009 | 1104 | 0.130 |
Why?
|
| Body Composition | 5 | 2014 | 764 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2022 | 12318 | 0.120 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2013 | 17 | 0.120 |
Why?
|
| Cyclic AMP | 3 | 2006 | 270 | 0.120 |
Why?
|
| Free Radical Scavengers | 2 | 2011 | 90 | 0.120 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2013 | 51 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3213 | 0.120 |
Why?
|
| Myocytes, Cardiac | 2 | 2009 | 503 | 0.120 |
Why?
|
| Sleep | 1 | 2020 | 770 | 0.120 |
Why?
|
| Uncoupling Protein 3 | 1 | 2012 | 9 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 316 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 84 | 0.120 |
Why?
|
| Rats, Mutant Strains | 1 | 2012 | 23 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 469 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2017 | 595 | 0.120 |
Why?
|
| Rats, Inbred SHR | 2 | 2010 | 55 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 4 | 2013 | 1702 | 0.120 |
Why?
|
| Blotting, Western | 6 | 2011 | 1247 | 0.120 |
Why?
|
| Prevalence | 1 | 2019 | 2434 | 0.120 |
Why?
|
| Peptides | 2 | 2016 | 874 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 2505 | 0.120 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 159 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 602 | 0.110 |
Why?
|
| Heterozygote | 1 | 2013 | 256 | 0.110 |
Why?
|
| Lymphocytosis | 1 | 1992 | 11 | 0.110 |
Why?
|
| Ion Channels | 1 | 2012 | 131 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 1195 | 0.110 |
Why?
|
| Pituitary Diseases | 1 | 1992 | 18 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2013 | 127 | 0.110 |
Why?
|
| Hydrogen Peroxide | 2 | 2011 | 300 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 392 | 0.110 |
Why?
|
| Cytokines | 3 | 2012 | 1946 | 0.110 |
Why?
|
| Enzyme Activation | 4 | 2010 | 883 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 159 | 0.110 |
Why?
|
| 3T3 Cells | 4 | 2000 | 147 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2013 | 368 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2006 | 351 | 0.100 |
Why?
|
| Rats, Inbred WKY | 4 | 2013 | 45 | 0.100 |
Why?
|
| Dietary Fats | 2 | 2013 | 353 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 137 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2016 | 606 | 0.100 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 2525 | 0.100 |
Why?
|
| Fatty Acids | 2 | 2018 | 417 | 0.100 |
Why?
|
| Mitogens | 2 | 2009 | 65 | 0.100 |
Why?
|
| Casein Kinase II | 1 | 2010 | 23 | 0.100 |
Why?
|
| Placebos | 3 | 2019 | 211 | 0.100 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2009 | 109 | 0.100 |
Why?
|
| Receptors, LDL | 1 | 2010 | 39 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1992 | 304 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 285 | 0.100 |
Why?
|
| Vitamin D | 1 | 2013 | 360 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2020 | 3268 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 4621 | 0.100 |
Why?
|
| Uracil | 1 | 2009 | 36 | 0.090 |
Why?
|
| Longevity | 2 | 2022 | 187 | 0.090 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2007 | 64 | 0.090 |
Why?
|
| Receptors, Glucagon | 1 | 2009 | 23 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 363 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 58 | 0.090 |
Why?
|
| Cardiac Output, Low | 1 | 2009 | 78 | 0.090 |
Why?
|
| Calcium | 2 | 1993 | 1205 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 454 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2006 | 2748 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 1992 | 410 | 0.090 |
Why?
|
| Diet | 4 | 2019 | 1116 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 356 | 0.080 |
Why?
|
| Transcription, Genetic | 4 | 2009 | 1409 | 0.080 |
Why?
|
| Piperidines | 1 | 2009 | 174 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2009 | 254 | 0.080 |
Why?
|
| Genes, Dominant | 2 | 2007 | 98 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 5137 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2009 | 253 | 0.080 |
Why?
|
| Gene Expression | 1 | 2013 | 1517 | 0.080 |
Why?
|
| Sequence Deletion | 2 | 1999 | 180 | 0.080 |
Why?
|
| Luciferases | 3 | 2005 | 148 | 0.080 |
Why?
|
| Sports | 1 | 2009 | 173 | 0.080 |
Why?
|
| HIV Infections | 1 | 2021 | 2510 | 0.080 |
Why?
|
| Time Factors | 3 | 2014 | 6905 | 0.080 |
Why?
|
| Perception | 1 | 2009 | 313 | 0.080 |
Why?
|
| Vasodilator Agents | 2 | 2013 | 335 | 0.080 |
Why?
|
| Cholesterol | 2 | 2013 | 392 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 1992 | 474 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2013 | 874 | 0.080 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2006 | 33 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 2542 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 1144 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 400 | 0.070 |
Why?
|
| Oxidants | 2 | 2005 | 125 | 0.070 |
Why?
|
| Creatinine | 2 | 2020 | 472 | 0.070 |
Why?
|
| Food Deprivation | 1 | 2006 | 27 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2697 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 135 | 0.070 |
Why?
|
| Fibrinolysis | 3 | 2003 | 203 | 0.070 |
Why?
|
| Cell Proliferation | 5 | 2013 | 2368 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 347 | 0.070 |
Why?
|
| Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.070 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 88 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 194 | 0.070 |
Why?
|
| Fetus | 2 | 2021 | 667 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 623 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2006 | 321 | 0.070 |
Why?
|
| Fasting | 1 | 2005 | 273 | 0.060 |
Why?
|
| Olfactory Mucosa | 1 | 2004 | 59 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2004 | 98 | 0.060 |
Why?
|
| Anthracenes | 1 | 2003 | 31 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2003 | 31 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2017 | 220 | 0.060 |
Why?
|
| Rats, Zucker | 2 | 2017 | 36 | 0.060 |
Why?
|
| Glucose Oxidase | 1 | 2003 | 19 | 0.060 |
Why?
|
| Bromocriptine | 1 | 2022 | 30 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2004 | 344 | 0.060 |
Why?
|
| Arteries | 2 | 2016 | 241 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2003 | 62 | 0.060 |
Why?
|
| Tyrosine | 1 | 2004 | 239 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 87 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2942 | 0.060 |
Why?
|
| Adult Children | 1 | 2022 | 17 | 0.060 |
Why?
|
| Vitamin E | 1 | 2003 | 124 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2010 | 900 | 0.060 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 112 | 0.060 |
Why?
|
| Regeneration | 1 | 2004 | 171 | 0.060 |
Why?
|
| Carnitine | 1 | 2022 | 70 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2016 | 525 | 0.060 |
Why?
|
| Fetal Heart | 1 | 2022 | 51 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2021 | 60 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 269 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 922 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 51 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2001 | 199 | 0.050 |
Why?
|
| Parathyroid Hormone | 2 | 1993 | 116 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1755 | 0.050 |
Why?
|
| Arginine | 1 | 2003 | 257 | 0.050 |
Why?
|
| Cell Death | 2 | 2016 | 344 | 0.050 |
Why?
|
| Base Sequence | 2 | 2009 | 2170 | 0.050 |
Why?
|
| Hemoglobin, Sickle | 1 | 2021 | 8 | 0.050 |
Why?
|
| Housing | 1 | 2022 | 117 | 0.050 |
Why?
|
| Respiration | 1 | 2022 | 196 | 0.050 |
Why?
|
| Heart Function Tests | 2 | 2013 | 75 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2022 | 171 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 498 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 371 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 175 | 0.050 |
Why?
|
| Medicare | 2 | 2022 | 718 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2021 | 208 | 0.050 |
Why?
|
| Placental Insufficiency | 1 | 2021 | 95 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 420 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2020 | 458 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2016 | 408 | 0.050 |
Why?
|
| Myelin P2 Protein | 1 | 2000 | 2 | 0.050 |
Why?
|
| Fatty Acid-Binding Protein 7 | 1 | 2000 | 3 | 0.050 |
Why?
|
| Poverty | 1 | 2004 | 450 | 0.050 |
Why?
|
| Phenylbutazone | 1 | 2020 | 2 | 0.050 |
Why?
|
| Tolbutamide | 1 | 2020 | 9 | 0.050 |
Why?
|
| Bucladesine | 1 | 2000 | 24 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 2896 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2000 | 70 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 309 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 194 | 0.050 |
Why?
|
| Oxazoles | 1 | 2020 | 31 | 0.050 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2013 | 137 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 159 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 3206 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2000 | 84 | 0.050 |
Why?
|
| Government Regulation | 1 | 2020 | 48 | 0.050 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2000 | 56 | 0.050 |
Why?
|
| Systole | 1 | 2020 | 189 | 0.050 |
Why?
|
| Physicians, Women | 1 | 2020 | 52 | 0.050 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 30 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2000 | 109 | 0.050 |
Why?
|
| Cell Transdifferentiation | 1 | 2019 | 34 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 1438 | 0.050 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 1999 | 2 | 0.050 |
Why?
|
| Linear Models | 2 | 2014 | 873 | 0.050 |
Why?
|
| Mutation | 2 | 2007 | 3406 | 0.050 |
Why?
|
| Chromogranins | 1 | 1999 | 14 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2001 | 226 | 0.050 |
Why?
|
| Proteins | 2 | 1996 | 912 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 766 | 0.050 |
Why?
|
| Sheep | 1 | 2021 | 747 | 0.050 |
Why?
|
| Macrophages | 1 | 2006 | 1330 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2000 | 346 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 158 | 0.050 |
Why?
|
| PPAR alpha | 2 | 2010 | 59 | 0.050 |
Why?
|
| Glycine | 1 | 2020 | 170 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 185 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 44 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 269 | 0.040 |
Why?
|
| Chromogranin A | 1 | 1999 | 40 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2018 | 63 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 202 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2010 | 35 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 68 | 0.040 |
Why?
|
| Pulmonary Circulation | 2 | 2013 | 443 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 218 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 389 | 0.040 |
Why?
|
| Diet, Western | 1 | 2018 | 67 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 556 | 0.040 |
Why?
|
| Phenylephrine | 1 | 2018 | 94 | 0.040 |
Why?
|
| Hematocrit | 1 | 2018 | 99 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2018 | 149 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 206 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2020 | 260 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 354 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 1133 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 157 | 0.040 |
Why?
|
| Hippocampus | 1 | 2003 | 811 | 0.040 |
Why?
|
| Antioxidants | 1 | 2001 | 586 | 0.040 |
Why?
|
| Cell Membrane | 3 | 2004 | 728 | 0.040 |
Why?
|
| Adenosine Triphosphate | 2 | 2017 | 448 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 539 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 422 | 0.040 |
Why?
|
| Insulin Glargine | 1 | 2017 | 70 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 321 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 157 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 314 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2019 | 291 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 138 | 0.040 |
Why?
|
| Phosphorus Radioisotopes | 2 | 1993 | 33 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 926 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 239 | 0.040 |
Why?
|
| Binding Sites | 1 | 2000 | 1259 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 554 | 0.040 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 42 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 414 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 661 | 0.040 |
Why?
|
| Estradiol | 1 | 2019 | 465 | 0.040 |
Why?
|
| Placenta | 1 | 2021 | 604 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 920 | 0.040 |
Why?
|
| Nitrendipine | 2 | 1993 | 13 | 0.040 |
Why?
|
| Collagen | 2 | 2009 | 426 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 1995 | 31 | 0.040 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 1995 | 9 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2000 | 759 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 283 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 5106 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 268 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 251 | 0.030 |
Why?
|
| Lovastatin | 1 | 1995 | 34 | 0.030 |
Why?
|
| Glycogen | 1 | 1995 | 62 | 0.030 |
Why?
|
| Heart Rate | 3 | 2009 | 795 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1994 | 68 | 0.030 |
Why?
|
| Cystatin C | 1 | 2014 | 70 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1995 | 63 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 365 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 353 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 465 | 0.030 |
Why?
|
| Phosphorus | 1 | 2014 | 91 | 0.030 |
Why?
|
| Fatty Acid Synthases | 2 | 2006 | 33 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 25 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 2107 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2009 | 708 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 470 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 118 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 1993 | 48 | 0.030 |
Why?
|
| Lipolysis | 1 | 2013 | 50 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 56 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 163 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2013 | 31 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 710 | 0.030 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 65 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 991 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2013 | 76 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1143 | 0.030 |
Why?
|
| Reference Values | 2 | 2007 | 836 | 0.030 |
Why?
|
| Optic Chiasm | 1 | 1992 | 17 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2007 | 329 | 0.030 |
Why?
|
| Nerve Compression Syndromes | 1 | 1992 | 29 | 0.030 |
Why?
|
| Physicians | 1 | 2020 | 771 | 0.030 |
Why?
|
| Premenopause | 2 | 2003 | 122 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2004 | 579 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1966 | 0.030 |
Why?
|
| Thyrotropin | 1 | 1992 | 106 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 282 | 0.030 |
Why?
|
| Colorado | 2 | 2017 | 4401 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 1992 | 70 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1992 | 52 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1317 | 0.030 |
Why?
|
| Potassium | 1 | 1991 | 149 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2016 | 756 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1992 | 154 | 0.030 |
Why?
|
| Vision Disorders | 1 | 1992 | 138 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1585 | 0.020 |
Why?
|
| Headache | 1 | 1992 | 170 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 2016 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 184 | 0.020 |
Why?
|
| Inflammation | 3 | 2009 | 2537 | 0.020 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 244 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 42 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2009 | 51 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 469 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2009 | 74 | 0.020 |
Why?
|
| Plethysmography | 1 | 2009 | 141 | 0.020 |
Why?
|
| Swimming | 1 | 2009 | 51 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 587 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 352 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 232 | 0.020 |
Why?
|
| Hormones | 1 | 2009 | 134 | 0.020 |
Why?
|
| Puberty | 1 | 2009 | 136 | 0.020 |
Why?
|
| Myoglobin | 1 | 2007 | 16 | 0.020 |
Why?
|
| Betacellulin | 1 | 2007 | 7 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4847 | 0.020 |
Why?
|
| Fenofibrate | 1 | 2007 | 26 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 51 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 219 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 425 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 134 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1405 | 0.020 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 2006 | 8 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4914 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 94 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2006 | 30 | 0.020 |
Why?
|
| Elastin | 1 | 2006 | 78 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2007 | 191 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 38 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 50 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 78 | 0.020 |
Why?
|
| Running | 1 | 2009 | 240 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 49 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2006 | 72 | 0.020 |
Why?
|
| Cadaver | 1 | 2007 | 311 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 68 | 0.020 |
Why?
|
| Caspases | 1 | 2007 | 276 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 117 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 91 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2006 | 129 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 6794 | 0.020 |
Why?
|
| RNA Stability | 1 | 2006 | 103 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2006 | 253 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2006 | 146 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 685 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 440 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 206 | 0.020 |
Why?
|
| Mice, Congenic | 1 | 2004 | 26 | 0.020 |
Why?
|
| Receptors, Odorant | 1 | 2004 | 32 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 405 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2003 | 43 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2004 | 255 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1050 | 0.020 |
Why?
|
| Patient Selection | 1 | 2007 | 698 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 3641 | 0.010 |
Why?
|
| Smell | 1 | 2004 | 110 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 312 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 903 | 0.010 |
Why?
|
| Serum Globulins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 668 | 0.010 |
Why?
|
| Imidazoles | 1 | 2003 | 246 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2002 | 93 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2001 | 24 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2001 | 39 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2002 | 161 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 1152 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 8243 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 786 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1164 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 471 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 242 | 0.010 |
Why?
|
| Densitometry | 1 | 1998 | 32 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1998 | 71 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1986 | 1401 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 711 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1996 | 20 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1996 | 47 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1998 | 282 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1996 | 14 | 0.010 |
Why?
|
| Chromones | 1 | 1996 | 40 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1996 | 93 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 147 | 0.010 |
Why?
|
| GTPase-Activating Proteins | 1 | 1996 | 69 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 121 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 273 | 0.010 |
Why?
|
| Morpholines | 1 | 1996 | 106 | 0.010 |
Why?
|
| Smoking | 1 | 2003 | 1654 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2004 | 1573 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1993 | 26 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1993 | 34 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1993 | 39 | 0.010 |
Why?
|
| Terpenes | 1 | 1993 | 23 | 0.010 |
Why?
|
| Neoplasms | 1 | 1986 | 2137 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 406 | 0.010 |
Why?
|
| Disulfiram | 1 | 1986 | 12 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1986 | 85 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1986 | 187 | 0.000 |
Why?
|
| Cisplatin | 1 | 1986 | 270 | 0.000 |
Why?
|